NASDAQ:MEDS
DataMeds AI, Inc.
DataMeds AI, Inc.'s revenue grew 28.7% in fiscal 2025 to $23.3M while operating margin fell to −401.7%. The diluted share count rose 50.2%.Summary generated from DataMeds AI, Inc.'s SEC filings. Latest annual report filed Mar 20, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$23.3M
Revenue growth+28.7%
Revenue, 5-yr CAGRn/a
Gross margin−27.5%
Operating margin−401.7%
Net margin−433.9%
ROIC−369.5%
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+50.2%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | 18 | 23 |
| Operating income | −3 | −6 | −94 |
| Net income | −3 | −7 | −101 |
| Free cash flow | n/a | n/a | n/a |
Recent filings
- 8-KOther events
Sep 17, 2026 - 8-KEntry into a material agreement
Sep 16, 2026 - 8-KResults of operations and financial condition
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 17, 2026 - 8-KOther events
Aug 14, 2026 - S-1Registration statement
Aug 7, 2026 - 8-KEntry into a material agreement
Aug 4, 2026 - 8-KOther events
Jul 29, 2026